Using Travelan to Boost Immune Response in Vitro to COVID-19

NCT04643561 | Unknown Phase 1

• 1 other identifier: healthytravelancov19- HMO-CTIL
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

The gut immune system was shown as an effective target for inducing systemic immune signals against viruses. Oral administration of Travelan, an over the counter product which contains hyperimmune bovine colostrum was shown in preclinical studies to augment the anti-viral immune towards several strains of influenza viruses (RNA viruses). This study will evaluate the option that Trevalan may help improve the immune system reaction when introduced to COVID-19 proteins in-vitro. 5 healthy volunteers will receive a treatment regimen of 5 days with Trevalan. Before and after treatment, blood samples will be taken in order to test immune response towards viral proteins of the COVID-19 virus in vitro by measuring the number of T cell clone secreting IFNγ against viral antigens.

Conditions

Covid19

Keywords

hyperimmune colostrum

Outcome Measures

Primary Outcomes (1)

• increase levels of IFNγ

  The primary objective of this study is to show an increase in levels of IFNγ against viral antigens after treatment regimen with Trevalan

  6 days

Secondary Outcomes (1)

• registering adverse events

  30 days

Study Arms (1)

intervention

EXPERIMENTAL

5 patients will recieve 5 days treatment with Travelan, blood samples will be taken prior and after intervention

Other: Travelan OTC

Interventions

Travelan OTC OTHER

5 days of treatment with Travelan food supplement 3 times a day, blood will be drawn prior and after intervention

intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult healthy volunteers aged 18 years old and above.
• No history of drug or alcohol abuse.
• Females of childbearing potential must be non-pregnant (as determined by a serum pregnancy test at screening and again, prior to each dosing session) and agree to use adequate contraceptive means throughout the study.
• Patients must be able to adhere to the visit schedule and protocol requirements and be available to complete the study.
• Patients must satisfy a medical examiner about their fitness to participate in the study.
• Patients must provide written informed consent to participate in the study

You may not qualify if:

• Acute illness resulting in emergency department (ED) evaluation or hospitalization in the last 6 month or any acute illness in the last month before enrollment
• Patients with evidence of other serious infectious, malignant, autoimmune, kidney, hepatic, or other non-cardiac systemic disease.
• Chronic drug therapy of any sort
• Known allergy to milk
• Over-the-counter drugs, including herbal medications, and prescription drugs (other than those listed above) are not allowed for 4 weeks prior to and throughout the duration of the study
• Participation in another clinical trial within 30 days prior to intervention.
• Patients with an inability to communicate well with the PI and staff (i.e., language problem, poor mental development or impaired cerebral function).
• Patients who will be unavailable for the duration of the trial, are likely to be noncompliant with the protocol, or who are felt to be unsuitable by the PI for any other reason.
• Known substance abuse, including inhaled or injected drugs in the year prior to Screening

Sponsors & Collaborators

• Hadassah Medical Organization: lead

Study Sites (1)

Hadassah Medical Organization, Jerusalem, Israel

Jerusalem, Israel

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD

Study Record Dates

• First Submitted: November 24, 2020
• First Posted: November 25, 2020
• Study Start: November 1, 2020
• Primary Completion: December 31, 2020
• Study Completion: December 31, 2020
• Last Updated: November 27, 2020

Record last verified: 2020-11

Locations

IL (1)